JP2012501648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501648A5 JP2012501648A5 JP2011526137A JP2011526137A JP2012501648A5 JP 2012501648 A5 JP2012501648 A5 JP 2012501648A5 JP 2011526137 A JP2011526137 A JP 2011526137A JP 2011526137 A JP2011526137 A JP 2011526137A JP 2012501648 A5 JP2012501648 A5 JP 2012501648A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- hvr
- seq
- antibody
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 15
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 9
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 claims 5
- 230000010261 cell growth Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 229940124650 anti-cancer therapies Drugs 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19085608P | 2008-09-03 | 2008-09-03 | |
| US61/190,856 | 2008-09-03 | ||
| PCT/US2009/055625 WO2010027981A1 (en) | 2008-09-03 | 2009-09-01 | Multispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501648A JP2012501648A (ja) | 2012-01-26 |
| JP2012501648A5 true JP2012501648A5 (enExample) | 2012-10-18 |
| JP5796831B2 JP5796831B2 (ja) | 2015-10-21 |
Family
ID=41399375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526137A Expired - Fee Related JP5796831B2 (ja) | 2008-09-03 | 2009-09-01 | 多重特異性抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8193321B2 (enExample) |
| EP (1) | EP2324061B1 (enExample) |
| JP (1) | JP5796831B2 (enExample) |
| KR (1) | KR101705911B1 (enExample) |
| CN (1) | CN102143977B (enExample) |
| AR (1) | AR073538A1 (enExample) |
| AU (1) | AU2009288167B2 (enExample) |
| BR (1) | BRPI0918648A2 (enExample) |
| CA (1) | CA2734905A1 (enExample) |
| ES (1) | ES2628108T3 (enExample) |
| IL (1) | IL211349A0 (enExample) |
| MX (1) | MX353984B (enExample) |
| PE (2) | PE20110593A1 (enExample) |
| PH (1) | PH12013502230A1 (enExample) |
| RU (1) | RU2547596C2 (enExample) |
| SG (1) | SG193851A1 (enExample) |
| TW (1) | TWI487712B (enExample) |
| WO (1) | WO2010027981A1 (enExample) |
| ZA (1) | ZA201101970B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| CN102143977B (zh) | 2008-09-03 | 2014-08-06 | 霍夫曼-拉罗奇有限公司 | 多特异性抗体 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AU2011257121A1 (en) | 2010-05-27 | 2013-01-10 | Genmab A/S | Monoclonal antibodies against HER2 |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| WO2012098113A1 (en) * | 2011-01-17 | 2012-07-26 | Novo Nordisk A/S | Il-21 ligands |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| KR20140057356A (ko) | 2011-08-31 | 2014-05-12 | 제넨테크, 인크. | 진단 마커 |
| KR101453516B1 (ko) | 2011-09-20 | 2014-10-24 | 가톨릭대학교 산학협력단 | 항-ｖｅｇｆ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물 |
| WO2013055530A1 (en) | 2011-09-30 | 2013-04-18 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| EP2862875B1 (en) | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| WO2014134169A1 (en) * | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| ES2989110T3 (es) * | 2013-11-11 | 2024-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que contiene región variable de anticuerpo modificada |
| JP2015097496A (ja) * | 2013-11-19 | 2015-05-28 | 国立大学法人 東京大学 | Ｒｏｂｏ１に対する親和性を向上させた抗体及び高親和性抗体の分子設計方法 |
| WO2015119841A1 (en) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Role of il-23 and pd-1 in autoreactive immune response |
| GB201411420D0 (en) * | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| WO2016042684A1 (ja) * | 2014-09-16 | 2016-03-24 | 国立大学法人東京海洋大学 | 濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法 |
| KR102390359B1 (ko) | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| TWI740809B (zh) * | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
| CN107106682B (zh) | 2015-08-26 | 2021-05-25 | 比森医疗股份有限公司 | 多特异性抗体平台和相关方法 |
| IL257565B2 (en) | 2015-09-23 | 2024-08-01 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| GB201521447D0 (en) | 2015-12-04 | 2016-01-20 | Ucb Biopharma Sprl | De novo antibody design |
| WO2017132457A1 (en) * | 2016-01-28 | 2017-08-03 | Janssen Biotech, Inc. | BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE |
| WO2018224550A1 (en) * | 2017-06-07 | 2018-12-13 | Philogen S.P.A | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| CN107602702A (zh) * | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
| AU2019315226B2 (en) | 2018-08-03 | 2025-09-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| WO2020067399A1 (en) | 2018-09-28 | 2020-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| US12392777B2 (en) | 2019-04-02 | 2025-08-19 | National Research Council Of Canada | Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors |
| IL296803A (en) | 2020-03-31 | 2022-11-01 | Chugai Pharmaceutical Co Ltd | Multispecific antigen binding molecules targeting dll3 and their uses |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| WO1992010209A1 (en) | 1990-12-04 | 1992-06-25 | The Wistar Institute Of Anatomy And Biology | Bifunctional antibodies and method of preparing same |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| CZ287296B6 (en) | 1992-01-23 | 2000-10-11 | Merck Patent Gmbh | Antibody construct and structural kit for selective preparation thereof |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| EP2386575A3 (en) | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| JP2002355074A (ja) * | 2001-01-24 | 2002-12-10 | Univ Tsukuba | 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法 |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2003018749A2 (en) | 2001-08-22 | 2003-03-06 | Shengfeng Li | Compositions and methods for generating antigen-binding units |
| EP1513879B1 (en) * | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| RS20181002A1 (sr) | 2003-05-30 | 2018-12-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| HRP20120376T1 (hr) | 2003-12-23 | 2012-05-31 | Genentech | Nova protutijela protiv il-13 i njihove upotrebe |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| KR20070041781A (ko) | 2004-08-11 | 2007-04-19 | 트루비온 파마슈티칼스, 인코포레이티드 | 결합 도메인 융합 단백질 |
| EP1968633B2 (en) | 2006-01-04 | 2017-11-01 | Institut National de la Santé et de la Recherche Medicale | Combination therapy using anti-egfr and anti-her2 antibodies |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK2059533T3 (da) * | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| WO2009068649A2 (en) | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| CN102143977B (zh) | 2008-09-03 | 2014-08-06 | 霍夫曼-拉罗奇有限公司 | 多特异性抗体 |
-
2009
- 2009-09-01 CN CN200980134512.4A patent/CN102143977B/zh not_active Expired - Fee Related
- 2009-09-01 BR BRPI0918648A patent/BRPI0918648A2/pt not_active IP Right Cessation
- 2009-09-01 US US12/552,177 patent/US8193321B2/en not_active Expired - Fee Related
- 2009-09-01 RU RU2011112324/10A patent/RU2547596C2/ru not_active IP Right Cessation
- 2009-09-01 MX MX2011002389A patent/MX353984B/es active IP Right Grant
- 2009-09-01 CA CA2734905A patent/CA2734905A1/en not_active Abandoned
- 2009-09-01 SG SG2013066501A patent/SG193851A1/en unknown
- 2009-09-01 AU AU2009288167A patent/AU2009288167B2/en not_active Ceased
- 2009-09-01 TW TW098129415A patent/TWI487712B/zh not_active IP Right Cessation
- 2009-09-01 JP JP2011526137A patent/JP5796831B2/ja not_active Expired - Fee Related
- 2009-09-01 EP EP09792139.9A patent/EP2324061B1/en not_active Not-in-force
- 2009-09-01 PE PE2011000442A patent/PE20110593A1/es not_active Application Discontinuation
- 2009-09-01 KR KR1020117007567A patent/KR101705911B1/ko not_active Expired - Fee Related
- 2009-09-01 AR ARP090103347A patent/AR073538A1/es unknown
- 2009-09-01 PE PE2014002488A patent/PE20150222A1/es not_active Application Discontinuation
- 2009-09-01 ES ES09792139T patent/ES2628108T3/es active Active
- 2009-09-01 WO PCT/US2009/055625 patent/WO2010027981A1/en not_active Ceased
-
2011
- 2011-02-18 US US13/030,760 patent/US9017686B2/en not_active Expired - Fee Related
- 2011-02-22 IL IL211349A patent/IL211349A0/en not_active IP Right Cessation
- 2011-03-15 ZA ZA2011/01970A patent/ZA201101970B/en unknown
-
2013
- 2013-10-30 PH PH12013502230A patent/PH12013502230A1/en unknown
-
2015
- 2015-03-23 US US14/665,697 patent/US9522960B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501648A5 (enExample) | ||
| RU2011112324A (ru) | Полиспецифические антитела | |
| JP2013538553A5 (enExample) | ||
| JP2013515485A5 (enExample) | ||
| JP2009541492A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2017501167A5 (enExample) | ||
| HRP20131107T1 (hr) | Anti-notch1 nrr-protutijela i postupak njihove uporabe | |
| JP2012525853A5 (enExample) | ||
| JP2012501626A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2014531201A5 (enExample) | ||
| EP3008093A1 (en) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer | |
| JP2015509947A5 (enExample) | ||
| JP2014522843A5 (enExample) | ||
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| JP2019513701A5 (enExample) | ||
| JP2010536378A5 (enExample) | ||
| JP2017502695A5 (enExample) | ||
| JP2012525149A5 (enExample) |